Vedolizumab - Takeda Oncology

Drug Profile

Vedolizumab - Takeda Oncology

Alternative Names: Entyvio; Kynteles; LDP-02; LPD-02; MLN-0002; MLN-002; MLN02

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Medical College of Wisconsin; Millennium; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Ulcerative colitis
  • Phase II Graft-versus-host disease
  • Phase I Malignant melanoma

Most Recent Events

  • 07 Nov 2017 Takeda and Portal Instruments agree to collaborate to develop a delivery device for vedolizumab
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in United Kingdom (SC, Injection)
  • 03 Nov 2017 Takeda plans a phase I pharmacokinetic trial for Crohn's Disease or Ulcerative colitis (In volunteers) in China in November 2017 (NCT03329209)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top